Background. Prospective evaluation of the value of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in monitoring disease activity and treatment response in patients with idiopathic retroperitoneal fibrosis (RPF). Methods. This study included 57 patients with idiopathic RPF receiving tamoxifen monotherapy with at least 8 months follow-up. Clinical, laboratory and radiological investigation was performed at presentation and at repeated follow-up. Remission was defined as significant clinical improvement within 6 weeks of treatment together with stable or decreasing mass size on follow-up computed tomography (CT) scanning at 4 months and definitive decrease in mass size on follow-up CT scanning at 8 months.
Introduction
Retroperitoneal fibrosis (RPF) is a rare collagen vascular disease, characterized by fibroinflammatory tissue, typically surrounding abdominal aorta and iliac arteries. It extends into the retroperitoneum, thereby possibly entrapping and obstructing surrounding structures, notably the ureters. RPF is generally idiopathic but can be secondary to certain drugs, malignant disease, infection and surgery [1] [2] [3] .
Nowadays, computed tomography (CT) and magnetic resonance imaging are the examinations of choice to diagnose RPF. These imaging techniques can visualize the extent of fibrosis and determine the possible presence of tumour or lymphadenopathy. Biopsy is sometimes needed to ascertain the diagnosis [1] [2] [3] .
Immunosuppressive therapy and/or hormonal therapy have largely replaced surgery as the treatment of choice. However, RPF displays a chronic relapsing course with medical treatment considered most effective in the active cellular phase as opposed to the late fibrotic phase [1] [2] [3] [4] .
Therefore, determining disease activity in patients with RPF disease is considered crucial in indicating potential response to medical treatment [2] [3] [4] .
By analogy to other chronic relapsing diseases [5] [6] [7] [8] , elevated acute-phase reactant levels are thought to represent active inflammation (i.e. the early active phase of RPF disease) and hence indicative of a potential response to medical treatment [1, 4, 9, 10] . However, in the only existing retrospective study investigating this assumption, no correlation was found between baseline erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels and subsequent therapeutic response to glucocorticoids [11] .
In this prospective study in a relatively large group of patients with idiopathic RPF, we evaluated the potential added role of baseline ESR and CRP levels and their respective changes during follow-up in assessing RPF disease activity and in predicting treatment response to tamoxifen.
Materials and methods

Patients
From April 1998 through January 2011, all patients at the Albert Schweitzer hospital with a diagnosis of idiopathic RPF who started tamoxifen monotherapy (20 mg two times daily) for first or recurrent presentation and who had at least 8 months follow-up were included in this prospective study. After careful exclusion of (occult) malignancy, the diagnosis of idiopathic RPF was based on characteristic clinical and CT findings, in 10 cases confirmed by histological examination of biopsy material. There was no history of infection or drugs that could have been associated with RPF. Emergency renal drainage was performed in case of severe obstructive renal failure. At baseline, age, sex, signs and symptoms and duration of symptoms were documented. Severity of symptoms at presentation was objectified by using the 100-mm horizontal visual analogue scale (VAS) for pain (abdominal, back and/or flank) and discomfort (e.g. significant loss of subjective well-being because of specific (e.g. pain) and/or non-specific symptoms (disturbed sleep, malaise, anorexia) [12] . Laboratory parameters included the ESR, CRP and serum creatinine. In addition to baseline abdominal CT scanning, dynamic nuclear scanning was performed routinely at baseline from April 1998 through June 2008. Tamoxifen treatment was started independent of the results of baseline laboratory tests or radiologic imaging. Follow-up included periodic clinical and laboratory examination (at 6 weeks, 4 months and 8 months of treatment), repeated CT scanning (at 4 and 8 months of treatment) and-if nuclear studies at baseline were 'positive' (see below)-repeat nuclear scanning after 3 months tamoxifen treatment. In case of diagnostic doubt during follow-up, histological examination of CT-guided biopsy was performed. The study complied with the Declaration of Helsinki. All patients provided informed consent to scheduling tests and imaging as well as to tamoxifen treatment.
Acute-phase reactants ESR was measured using capillary stopped flow kinetic analysis, which outcomes were converted to Westergren's values. Normal range varied according to sex: 0-25 mm/h in men aged ≤70 years, 0-30 mm/h in men aged >70 years, 0-30 mm/h in women aged ≤70 years and 0-35 mm/h in women aged >70 years. CRP was measured using immunoturbidimetric tests. Normal range for both men and women was 0-10 mg/L.
Computed tomography
All examinations were performed on the same scanner (Brilliance 64 multislice CT scan; Philips Medical Systems) following a similar protocol. Two independent experienced radiologists, who were unaware of the patient's status, reviewed all CT scans. Maximal thickness of the mass was measured in three different view directions (i.e. anterior-posterior, left lateral and transversal direction). To objectify changes within patients during follow-up, the largest value of the initial three different measurements of maximal thickness was compared to the thickness of the mass at each follow-up CT scan, using the same measurement direction and the same scan level from which the largest value was obtained on the first CT scan. The initial measurement of craniocaudal length was compared to the craniocaudal length of the mass at each follow-up CT scan. At each time of CT follow-up, the absolute decrease in mass thickness (Δthickness; mm) and craniocaudal length (ΔccLength; mm) were calculated.
Nuclear imaging
Nuclear scanning with 67-Gallium single-photon emission tomography ( 67 Ga SPECT) and/or 18 F-FDG uptake at the same position as the CT-documented mass was classified as positive. In patients with positive nuclear study at presentation, followup nuclear scanning was performed after 3 months of tamoxifen treatment. All nuclear scans were independently reviewed by two experienced nuclear medicine physicians who were unaware of the patient's status. Pathologic uptake was visually scored (0 to +3) compared with (normal) bone marrow uptake for 67 Ga and with (normal) liver uptake for 18 F-FDG, as previously described [10, 13] . Disagreements were resolved by consensus. Decrease in pathologic uptake following initiation of tamoxifen was measured as the absolute difference between the visual gallium or PET scan score on the first and second nuclear scan (ΔGa 67 or Δ 18 F-FDG score).
Measurements
Age, sex, clinical signs and symptoms, duration of symptoms, VAS scores for pain and discomfort, laboratory parameters (ESR, CRP, serum creatinine), nuclear scanning results and CT findings were documented at baseline. Follow-up measurements included clinical improvement, time to substantial resolution of symptoms, changes in laboratory parameters and follow-up findings of nuclear and CT scans. In patients who had elevated baseline levels of acute-phase reactants, (near-)normalization of acute-phase reactants at 6 weeks follow-up was defined as ESR or CRP levels within the normal range or <30% of respective baseline values. The primary end point was remission induced by tamoxifen monotherapy. Criteria for remission were significant clinical improvement within 6 weeks of tamoxifen treatment together with documented stable or decreasing mass size on the prescribed follow-up CT scan at 4 months and documented definitive decrease in mass size on the prescribed follow-up CT scan at 8 months. Because of the unclear predictive value, results of follow-up laboratory investigation and nuclear scanning were not part of the predefined criteria for remission. Secondary end points included changes in follow-up clinical, laboratory and radiological variables. Criteria for relapse were aggravation or return of clinical signs and/or symptoms (e.g. pain, hydroureteronephrosis) and/or CT-documented increase in mass size after 8 months of follow-up in patients who were in remission with tamoxifen monotherapy.
Statistical analysis
Because of non-Gaussian distribution of several study variables, continuous variables were reported as median and 25th-75th percentile and analysed by Mann-Whitney or Wilcoxon signed rank-sum test, where appropriate. Categorical variables were expressed as proportions and compared with Fisher's exact test. Spearman's rank correlation coefficient was used to test the association between acute-phase reactants and other parameters at baseline and at follow-up. We performed age-and sex-adjusted regression analyses on the relation between log-transformed baseline acute-phase reactants and VAS score for pain and discomfort, adding potential confounders one at a time to the model containing logtransformed baseline ESR/CRP, age and sex. Kaplan-Meier method was used to analyse time to switch of therapy (i.e. treatment failure) in patients with normal or elevated baseline ESR/CRP levels and in patients with or without (near-)normalization of ESR/CRP levels at 6 weeks in patients with elevated ESR or CRP at presentation. All reported P-values are two sided. A P-value of <0.05 was considered significant. All statistical analyses were performed with SPSS software (version 16.0; SPSS Inc., Chicago, IL).
Results
The study group consisted of 57 patients who fulfilled the criteria of idiopathic RPF and who had at least 8 months follow-up. During the study period, none of the patients discontinued tamoxifen therapy because of side effects. Demographic and clinical characteristics of these patients are depicted in Table 1 . Sixty-nine per cent of patients had elevated levels of ESR and/or CRP at presentation: 50% of patients had elevated levels of both ESR and CRP, 9.5% of patients had elevated ESR but normal CRP level and 9.5% of patients had elevated CRP but normal ESR level. Baseline ESR and CRP levels correlated significantly with each other (r = 0.68; P < 0.001). Patients with elevated baseline ESR or CRP levels had higher VAS scores for pain compared to patients with normal baseline ESR or CRP levels. Patients with elevated baseline ESR also had significantly higher VAS scores for discomfort (Table 1) . A positive PET scan result at presentation was found more often in patients with elevated acute-phase reactants compared to patients with normal baseline values, albeit not statistically significant. Otherwise, there were no differences in other study variables between patients who presented with normal or elevated ESR or CRP (Table 1) . Baseline ESR and CRP correlated significantly with the VAS score for pain.
Baseline ESR also correlated significantly with VAS score for discomfort (Table 2) . Multiple regression analysis on the correlation between log-transformed baseline ESR and CRP levels and VAS score for pain (Figure 1 ), adjusted for age and sex (ESR, P < 0.01; CRP, P < 0.01), showed that this was independent of duration of symptoms, serum creatinine, presence of hydroureteronephrosis and mass thickness. The correlation between log-transformed ESR and VAS score for discomfort (Figure 1 ), adjusted for age and sex (ESR, P < 0.01), was dependent of serum creatinine (P = 0.02) but not of the other possible confounders. Baseline CRP and to some extent ESR correlated with the presence of hydroureteronephrosis (Table 2) . Baseline ESR and CRP correlated with the PET scan score at presentation. Baseline ESR also correlated with the decrease in gallium as well as PET scan score after 3 months (Table 2) . During follow-up, 48 patients reported substantial resolution of symptoms after a median treatment duration of 3 weeks (1.4-4.7 weeks). There was a gradual and persistent decrease in acute-phase reactant levels over time following tamoxifen treatment ( Figure 2 ). Respective decreases in ESR and CRP levels during follow-up correlated significantly with each other (each time point P < 0.01). Decrease in ESR or CRP over time did not correlate with amelioration of symptoms nor with the time to a amelioration of symptoms (Table 3) . Decrease in ESR over time correlated significantly with decrease in PET scan score, particularly at 4 and 8 months of follow-up, and to a lesser extent with decrease in gallium scan score (Table 3) . Short-term decreases in ESR or CRP at 6 weeks follow-up did not correlate with subsequent CTdocumented mass regression (Table 3) . Decrease in ESR at 4 months follow-up correlated with CT-documented mass regression. Decrease in CRP at 4 and 8 months follow-up correlated with mass regression (Table 3 ). In 41 patients (72%), tamoxifen treatment was considered successful. Fifteen patients received second-line treatment after a median treatment duration of 5 months (range 1-8 months). One patient who failed therapy refused secondline therapy. There was no difference in individual outcome parameters or in remission rate between patients with normal or elevated baseline acute-phase reactants (Table 4) . Kaplan-Meier analysis showed no difference in remission rate between patients who presented with normal or elevated ESR or CRP (log-rank P = 0.22 and P = 0.88, respectively). In the subgroup of patients with elevated acute-phase reactant level at baseline (either ESR or CRP), there was no difference in remission rate between patients with or without (near-)normalization of ESR or CRP in the first 6 weeks of treatment (log-rank P = 0.12 and P = 0.32, respectively).
Discussion
This prospective study shows that the majority of patients with idiopathic RPF have elevated ESR and/or CRP levels at presentation. Hence, RPF disease should be seriously considered in the evaluation of patients with 'typical' complaints such as lower back, flank and/or abdominal pain, weight loss and constipation [1, 2] and elevated acute-phase reactants. Conversely, the possibility of idiopathic RPF disease should not be excluded in patients with these complaints who do not have elevated acute-phase reactant levels. A major finding of our study is that patients with elevated acute-phase reactant levels are more symptomatic at presentation, i.e. they experience more pain and discomfort, but they do not have more extensive disease as illustrated by similar RPF mass thickness and similar percentage of hydroureteronephrosis. This association remained significant after adjusting for these possible confounders. However, the relation between the level of discomfort and ESR was in part determined by the serum creatinine level. Taken together, these results suggests that symptoms are primarily determined by the amount of inflammation and to lesser extent by the severity of renal failure but not by the presence of anatomically extensive disease and/or the presence of hydroureteronephrosis per se. Possibly, the higher creatinine level reflects the severity of hydroureteronephrosis, which as such may contribute to the higher level of discomfort.
Our study also shows that in most patients, elevated acute-phase reactant levels will decrease over time following initiation of tamoxifen treatment. However, acutephase reactants at baseline nor their initial decrease at 6 weeks follow-up predicted the secondary end points of amelioration of symptoms or mass regression. This suggests that baseline acute-phase reactant levels or their initial changes following treatment initiation cannot be taken as a major predictor of a definitive therapeutic response before the follow-up evaluation with CT scanning. Indeed, acute-phase reactant levels at baseline nor their decreases at repeated follow-up predicted the primary end point of remission. However, decreases in acute-phase reactant levels at later time points during follow-up, notably CRP level, correlated with CT-documented mass regression following tamoxifen treatment. As such, the initial decrease in acute-phase reactant levels following initiation of tamoxifen monotherapy may be reassuring as to the presumed diagnosis, particularly in the absence of histologic confirmation of RPF disease, which is common practice nowadays. Recognizing the potential pitfall of malignant lymphoma, this may also be true for the response to corticosteroid therapy. Nevertheless, repeated CT scanning remains the mainstay to assess mass regression and to assess if retroperitoneal structures are (no longer) in danger of being compromised. As normal acute-phase reactant levels at presentation did not preclude a good response to tamoxifen therapy in our study, tamoxifen may also be efficacious in both early and later stages of RPF disease [10, 14] . Generally, the combination of severe symptoms and significantly increased levels of acute-phase reactants is taken as the starting point for medical treatment, as it would suggest that RPF disease was in the active cellular phase and therefore sensitive to immunosuppressive therapy [2] [3] [4] . To date, however, only one study has formally investigated this assumption [11] . In this retrospective study in 37 patients, baseline levels of ESR and CRP were not associated with treatment success, as defined by CT-documented mass regression following initiation of corticosteroids. Interpretation of results is made difficult because of differences in the timing of follow-up CT scanning. In addition, changes in acute-phase reactant levels were not analysed in relation to changes in mass size over time. While acknowledging CT-documented mass regression as a major outcome parameter, treatment success in clinical practice is the aggregate measure of clinical, laboratory and radiological improvement. For Fig. 1 . Univariate logistic regression showing a significant correlation between log-transformed ESR and CRP levels with the VAS score for pain and between log-transformed ESR levels and the VAS score for discomfort at presentation. These associations remained significant after adjusting for possible confounders, except for the relation between log-transformed ESR levels and VAS score for discomfort, which was influenced by the severity of renal failure (see text). example, some patients may have mass regression while still having debilitating symptoms, which may lead to altering the therapeutic approach.
Nuclear scanning may potentially be valuable in the diagnostic workup of RPF disease and in monitoring treatment response [2, 3] . In the present study, acute-phase reactant levels at presentation correlated with baseline PET scan score and to lesser extent with baseline gallium scan score. In addition, decrease in ESR correlated strongly with the decrease in PET scan score over time and to lesser extent with the decrease in gallium scan score over time. We previously found no association between the decrease in visual PET scan score at 3 months and subsequent CT-documented mass regression at further follow-up following initiation of tamoxifen therapy [10] . Given the strong association between PET scanning and acute-phase reactant levels, the question arises as to whether PET scanning is of added value in the evaluation of disease activity and in follow-up after initiating treatment or that it is no more than an expensive surrogate acute-phase reactant. We previously showed a significant association between the decrease in gallium scan score and subsequent mass regression at further follow-up [13] . Thus, compared to 18 FDG-PET, 67 Ga SPECT may be more useful as an additional tool in evaluating treatment response in patients with initial positive gallium scan, particularly when (serious) symptoms and/or increased acutephase reactants are absent. Both techniques also have disadvantages, including high costs and exposure to a radiation dose. 18 FDG-PET is still significantly more expensive than 67 Ga SPECT but can be combined with CT scanning. Conversely, the radiation dose with gallium scanning is larger and the technique more time consuming.
These disadvantages and the present results make it plausible to leave nuclear scanning out in the general diagnostic and therapeutic workup of RPF disease and to reserve its place for objectifying suspected active disease in patients without (serious) symptoms and/or normal acute-phase reactants and for objectifying suspected recurrent disease in previously treated patients with recurrent symptoms in the absence of elevated acute-phase reactants and/or stable residual mass. Our results do not indicate a preferential role for either ESR or CRP in the diagnostic or therapeutic workup of RPF disease. Despite multiple non-inflammatory factors influencing ESR [15, 16] and CRP [17, 18] levels, we found a strong correlation between both acute-phase reactants. In other chronic inflammatory diseases, no superiority of ESR or CRP as parameters for disease activity is evident [5, 7, 8, 19] . In some diseases (e.g. polymyalgia rheumatic, Wegener's granulomatosis), acute-phase reactants may be of value in predicting relapse [20] [21] [22] . The present study showed no association between pre-treatment acute-phase reactant levels and relapse rate.
The strength of this study is that it constitutes the largest and only prospective study of the value of acutephase reactants in the workup of RPF patients. In addition, this is the first study investigating if changes of acute-phase reactant levels following initiation of treatment have any predictive value. Our study also has limitations. As prescribed by the protocol, all patients received tamoxifen treatment regardless of baseline laboratory or imaging results. However, as the study was unblinded, one cannot exclude the possibility that results from repeated laboratory and/or nuclear scan investigation influenced treatment decisions during follow-up (e.g. at the time of suspected disease relapse). In addition, as all study patients underwent repeated laboratory investigation, the attributable portion of these results on top of CT scanning cannot be ascertained. For this, a study randomizing patients to receive either combined laboratory investigation and repeated CT scanning or repeated CT scanning only would be required.
In conclusion, RPF patients with elevated acute-phase reactant levels are more symptomatic at presentation. Our findings suggest that symptoms are caused by more intense inflammation rather than by more anatomically extensive disease or by the presence of hydroureteronephrosis. Neither acute-phase reactant levels at presentation or their initial changes following initiation of treatment can be taken as a major predictor for a definitive treatment response, but their short-term decrease can be reassuring as to the presumed diagnosis. These results do not suggest an important role for nuclear imaging in the diagnostic and therapeutic workup in RPF patients other than in selected cases, with gallium scanning adding more value than PET scanning.
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